Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315382 | 0.82 | CES2 (0.46) | KMT2AALDH1A1HPGDMEN1KDM4E | |
| SCHEMBL10384827 | 0.81 | ALDH1A1 (0.43) | LMNAKMT2AALDH1A1MAPK1AKR1C1 | |
| SCHEMBL16668009 | 0.81 | LMNA (0.41) | LMNAKMT2AALDH1A1AKR1C1HPGD | |
| SCHEMBL16576959 | 0.78 | LMNA (0.39) | LMNAALDH1A1MAPK1AKR1C1HPGD | |
| SCHEMBL26110622 | 0.78 | ALDH1A1 (0.41) | LMNAKMT2AALDH1A1TDP1AKR1C1 | |
| SCHEMBL8383354 | 0.78 | AKT1 (0.41) | LMNAKMT2AALDH1A1AKR1C1HPGD | |
| SCHEMBL10385929 | 0.77 | LMNA (0.38) | LMNAKMT2AALDH1A1AKR1C1HPGD | |
| SCHEMBL2960390 | 0.76 | LMNA (0.37) | LMNAALDH1A1AKR1C1HPGDHDAC4 | |
| SCHEMBL6549880 | 0.75 | AKT1 (0.35) | LMNAKMT2AALDH1A1AKR1C1HPGD | |
| SCHEMBL383939 | 0.75 | CYP2C19 (0.35) | AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044545-A1 | PHOTOCURABLE INKS FOR INDIRECT PRINTING METHOD | XEROX CORPORATION | 2018-02-15 | — | — | US | disclosed |
| US-20160333204-A1 | PHOTOCURABLE INKS FOR INDIRECT PRINTING | XEROX CORPORATION | 2016-11-17 | — | — | US | disclosed |
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9074105-B2 | Emulsified UV curable inks for indirect printing | XEROX CORPORATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150119487-A1 | EMULSIFIED UV CURABLE INKS FOR INDIRECT PRINTING | XEROX CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150116415-A1 | PHOTOCURABLE INKS FOR INDIRECT PRINTING | XEROX CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
| EP-2129659-B1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| EP-2129659-A1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008122504-A1 | ALPHA-HYDROXYKETONES | BASF SE (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | C9, C1R, CBR3 | LMNA 951/4885KMT2A 2928/4885ALDH1A1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.